34 related articles for article (PubMed ID: 10894819)
1. Modified sites and functional consequences of 4-oxo-2-nonenal adducts in HDL that are elevated in familial hypercholesterolemia.
May-Zhang LS; Yermalitsky V; Melchior JT; Morris J; Tallman KA; Borja MS; Pleasent T; Amarnath V; Song W; Yancey PG; Davidson WS; Linton MF; Davies SS
J Biol Chem; 2019 Dec; 294(50):19022-19033. PubMed ID: 31666337
[TBL] [Abstract][Full Text] [Related]
2. Serum Anti-Apo B Antibody Level as Residual CVD Marker in DM Patients under Statin Treatment.
Yamamoto H; Kawamura M; Kochi I; Imai M; Murata Y; Suzuki T; Chen Y; Hashimoto K; Kihara S
J Atheroscler Thromb; 2019 Oct; 26(10):931-943. PubMed ID: 30867375
[TBL] [Abstract][Full Text] [Related]
3. The Effects of Rope Training on Lymphocyte ABCA1 Expression, Plasma ApoA-I and HDL-c in Boy Adolescents.
Ghorbanian B; Ravassi A; Kordi MR; Hedayati M
Int J Endocrinol Metab; 2013; 11(2):76-81. PubMed ID: 23825977
[TBL] [Abstract][Full Text] [Related]
4. Computational lipidology: predicting lipoprotein density profiles in human blood plasma.
Hübner K; Schwager T; Winkler K; Reich JG; Holzhütter HG
PLoS Comput Biol; 2008 May; 4(5):e1000079. PubMed ID: 18497853
[TBL] [Abstract][Full Text] [Related]
5. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.
Zulewski H; Ninnis R; Miserez AR; Baumstark MW; Keller U
J Lipid Res; 1998 Feb; 39(2):380-7. PubMed ID: 9507998
[TBL] [Abstract][Full Text] [Related]
6. Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia.
Gaffney D; Forster L; Caslake MJ; Bedford D; Stewart JP; Stewart G; Wieringa G; Dominiczak M; Miller JP; Packard CJ
Atherosclerosis; 2002 May; 162(1):33-43. PubMed ID: 11947895
[TBL] [Abstract][Full Text] [Related]
7. Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs.
Schaefer JR; Scharnagl H; Baumstark MW; Schweer H; Zech LA; Seyberth H; Winkler K; Steinmetz A; März W
Arterioscler Thromb Vasc Biol; 1997 Feb; 17(2):348-53. PubMed ID: 9081691
[TBL] [Abstract][Full Text] [Related]
8. Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach.
Pietzsch J; Wiedemann B; Julius U; Nitzsche S; Gehrisch S; Bergmann S; Leonhardt W; Jaross W; Hanefeld M
J Lipid Res; 1996 Oct; 37(10):2074-87. PubMed ID: 8906585
[TBL] [Abstract][Full Text] [Related]
9. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
[TBL] [Abstract][Full Text] [Related]
10. Increased production of HDL ApoA-I in homozygous familial defective ApoB-100.
Schaefer JR; Winkler K; Schweer H; Hoffmann MM; Soufi M; Scharnagl H; Maisch B; Wieland H; Steinmetz A; März W
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1796-9. PubMed ID: 10894819
[TBL] [Abstract][Full Text] [Related]
11. Familial defective apolipoprotein B-100.
Hansen PS
Dan Med Bull; 1998 Sep; 45(4):370-82. PubMed ID: 9777289
[TBL] [Abstract][Full Text] [Related]
12. Familial defective apolipoprotein B-100: A review.
Andersen LH; Miserez AR; Ahmad Z; Andersen RL
J Clin Lipidol; 2016; 10(6):1297-1302. PubMed ID: 27919345
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
